Search

everythinglearnresearchcommunity

for

Search:↓

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The conversation discusses the completion of a Phase II trial recruitment for Breezula (CB-03-01), a potential treatment for androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.

The conversation discusses hair loss treatments, specifically using a regimen of minoxidil, finasteride, dutasteride, tretinoin, and microneedling. Users debate the optimal microneedling frequency, suggesting 1.5mm once every 1-2 weeks and 0.5mm every other day for better results.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

The user asks about the order and compatibility of using topical minoxidil, stemoxydine, The Ordinary natural moisturizing factors + HA for scalp, RU58841, and Nioxin system 2 leave-in treatment. They seek advice on layering these hair loss treatments.

Applying lavender essential oil before microneedling is discouraged due to potential skin irritation. Microneedling followed by oil application, like black castor oil, is more common and may benefit hair and scalp health.

The conversation discusses creating a topical hair loss treatment by dissolving melatonin in ethanol and possibly mixing it with castor oil, questioning the stability of the solution. An alternative of using glycerin is also considered.

A user is 6.5 months into using topical 5% minoxidil and 0.25% finasteride daily, with added Nizoral 2% and microneedling. They report hair thickening and regrowth on the hairline but seek advice on crown improvement, noting results can take up to a year.

A hair transplant of 3361 grafts, 11.5 months after the procedure, that resulted in a very natural looking NW1 hairline; the person who underwent this procedure has not experienced any hair loss and is expecting to have no future hairloss either.

A 23-year-old man shared his 4-month hair regrowth progress using 1mg oral finasteride daily, 5% minoxidil with finasteride topical twice a day, multivitamins, microneedling, head massages, and ketoconazole shampoo. He's unsure of his current Norwood scale classification and is asking for help to determine it, with suggestions ranging from NW4 to NW4.5.

The conversation is about the use of peptide therapies for hair loss, specifically GHK-CU, ZN-Thymulin, and PTD-DBM. The user is seeking feedback on the effectiveness of these treatments from those who have tried them.

The conversation is about the use of microneedling, specifically with a derma stamp, for hair regrowth. Users discuss their experiences, pain levels, and the satisfaction of taking control over hair loss, with some mentioning the use of Minoxidil to enhance results.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

RT1640, a combination of cyclosporin A, minoxidil, and RT175, is discussed as a potential treatment for hair regrowth and repigmentation. The unique formulation aims to enhance hair follicle growth and restore hair pigment without the negative side effects of immunosuppressants.

User discusses switching from microneedling to macroneeding for hair loss treatment. Suggestions include using various devices and unconventional methods.

GHK-Cu and Acetyl Tetrapeptide-3 are ineffective for hair regrowth according to user experiences. Effective treatments mentioned are finasteride, dutasteride, and minoxidil.

The user is using finasteride, oral minoxidil, Nizoral shampoo, and microneedling for hair loss treatment. They report progress and no sexual side effects, while others discuss dosage and the benefits of microneedling.

A 17-year-old with AGA is considering Revitacare Haircare Mesotherapy, which includes hyaluronic acid, amino acids, zinc, and B vitamins, injected into the scalp. One reply dismisses it as ineffective.

Clinical studies by Dr. Barghouthi and Dr. Bloxham indicate that Verteporfin, when used with FUE and FUT hair transplantation methods, shows promise in hair follicle regeneration and minimal scarring due to its ability to inhibit Yes-associated protein (YAP). Microneedling at depths of 3-3.5mm, combined with Verteporfin, could potentially reactivate dormant follicles, although the optimal dosage and application method are still under investigation. Concerns remain about the DHT sensitivity of regenerated follicles, highlighting the need for further research to optimize trauma levels and Verteporfin concentrations to achieve effective and scar-free hair regeneration.

The user is experiencing potential hair regrowth after 4 months of using a minoxidil and finasteride topical spray combined with microneedling 1-2 times a week. They notice some scalp redness and irritation but are unsure if the increased hair density is due to regrowth or longer hair.

The user shared their successful hair regrowth journey using minoxidil 5% twice daily and weekly microneedling. Other users suggested adding finasteride to maintain gains long-term.

The conversation is about the potential impact of RU58841 on male fertility, specifically regarding sperm concentration, total count, and motility. The user is curious about the likelihood of RU58841 reducing fertility based on its mechanism of action and comparisons to similar substances.